Verapamil

Verapamil is a calcium channel blocker and an orally active and effective inhibitor of P-gp. Verapamil inhibits CYP3A4 and can be used in studies about the treatment of high blood pressure, heart arrhythmias, and angina research. (In Vitro) :Verapamil inhibits the EverFluor FL Verapamil (EFV) uptake by TR-iBRB2 cells with an IC50 of 98.0 μM in a concentration-dependent manner. (In Vivo) :Verapamil (1 mg/kg; i.v.) significantly decreases the incidence of ventricular arrhythmias including premature ventricular contractions (PVC), ventricular tachycardia (VT) and ventricular fibrillation (VF) for 45-min coronary artery occlusion. Total arrhythmia scores are significantly increased when the heart is subjected to ischemia. Verapamil (1 mg/kg) significantly prevents the enhancement of total arrhythmia scores induced by ischemia. Verapamil (oral) is useful for the prophylaxis of atrioventricular reentry tachycardia, and also in modulating the atrioventricular nodal response in atrial fibrillation.

52-53-9

NSC 135784 | CP-16533-1 | (±) -Verapamil

Pharmacology & Drug Discovery

>98% (HPLC)

In Vitro: DMSO : 100 mg/mL (219.97 mM)

COc1ccc (CCN (C) CCCC (C#N) (C (C) C) c2ccc (OC) c (OC) c2) cc1OC

C27H38N2O4

454.611

Storage temperature: -20°C. Stability: ≥ 2 years